Quick Answer
GT Biopharma, Inc. reported Total Assets of $8.11 million for the year ending 2025.
- GT Biopharma, Inc. showed an increase of +87.6% in Total Assets from 2025 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $371.0 thousand | Q1 2012: $166.0 thousand | Q3 2012: $88.0 thousand | Q1 2013: $118.0 thousand | Q2 2013: $154.0 thousand | Q3 2013: $62.0 thousand | Q1 2014: $103.0 thousand | Q2 2014: $52.0 thousand | Q3 2014: $710.0 thousand | Q1 2015: $1.43 million | Q2 2015: $132.0 thousand | Q3 2015: $49.0 thousand | Q1 2016: $37.0 thousand | Q2 2016: $362.0 thousand | Q3 2016: $160.0 thousand | Q1 2017: $238.0 thousand | Q2 2017: $42.0 thousand | Q3 2017: $256.52 million | Q1 2018: $257.33 million | Q2 2018: $255.01 million | Q3 2018: $26.54 million | Q1 2019: $25.54 million | Q2 2019: $25.71 million | Q3 2019: $482.0 thousand | Q1 2020: $295.0 thousand | Q2 2020: $1.06 million | Q3 2020: $917.0 thousand | Q1 2022: $27.44 million | Q2 2022: $24.17 million | Q3 2022: $21.07 million | Q1 2023: $20.09 million | Q2 2023: $18.14 million | Q3 2023: $16.15 million | Q1 2024: $9.91 million | Q2 2024: $9.27 million | Q3 2024: $6.76 million.
- Over the full 18 years of available data (2010 to 2025), GT Biopharma, Inc.'s Total Assets has grown by 4,281.6%.
- Historical annual values: Fiscal year 2025: $8.11 million | Fiscal year 2025: $4.32 million | Fiscal year 2025: $7.12 million | Fiscal year 2024: $4.23 million | Fiscal year 2023: $14.11 million | Fiscal year 2022: $16.74 million | Fiscal year 2021: $32.17 million | Fiscal year 2020: $5.66 million | Fiscal year 2019: $396.0 thousand | Fiscal year 2018: $25.40 million | Fiscal year 2017: $254.37 million | Fiscal year 2016: $25.0 thousand | Fiscal year 2015: $54.0 thousand | Fiscal year 2014: $888.0 thousand | Fiscal year 2013: $147.0 thousand | Fiscal year 2012: $226.0 thousand | Fiscal year 2011: $129.0 thousand | Fiscal year 2010: $185.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: